Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Hi, could you provide a link to the paper
Key benefits Why people compare it 1 14.9% mean body weight reduction demonstrated in STEP 1 trial (N=1,961) 2 20% reduction in major adverse cardiovascular events in SELECT trial (N=17,604) 3 Significant reduction in appetite and food cravings via hypothalamic POMC/CART activation 4 Improved glycemic control with glucose-dependent insulin secretion potentiation 5 Once-weekly dosing enabled by 165-hour plasma half-life and albumin binding 6 86.4% of STEP 1 participants achieved at least 5% body weight loss 7 Demonstrated NAFLD/NASH improvement with reduction in liver fat content 8 Well-characterized safety profile from over 30,000 participants across STEP and SELECT programs Deep research Semaglutide (chemical name: N-epsilon26-[2-(2-[2-(2-[2-(2-((S)-2-carboxy-3-((1S,2R)-3-carboxy-1-(carboxymethyl-carbamoyl)-propylcarbamoyl)-propionylamino)-ethoxy)-ethoxy)-acetylamino]-ethoxy)-ethoxy)-acetyl]-[Aib8,Arg34]-GLP-1-(7-37)-peptide) is a 39-amino-acid peptide with a molecular weight of 4,113.58 Da
Taking an antiemetic (ondansetron 4mg, prochlorperazine 5mg) 30 minutes before injection can mitigate symptoms during titration, but dose reduction is the definitive solution
Vierteljahresschrift der Naturforschenden Gesellschaft in Zrich
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and -cell function in type 2 diabetes: a parallel-group study
US$ 25.77
US$ 25.34
US$ 26.01
US$ 21.42
US$ 20.30
US$ 29.66
US$ 23.39
US$ 28.88
